Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:heteroarylpiperidine
go back to main search page
Accession:CHEBI:48585 term browser browse the term
Synonyms:related_synonym: heteroarylpiperidines


show annotations for term's descendants           Sort by:
 
crizotinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
decreases activity
ISO crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]; crizotinib inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]
crizotinib results in decreased activity of ABCB1 protein
CTD PMID:22233293, PMID:28369651 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 decreases activity ISO crizotinib results in decreased activity of ABCG2 protein CTD PMID:28369651 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase decreases activity ISO crizotinib results in decreased activity of ABL1 protein CTD PMID:21812414 NCBI chr 3:10,041,820...10,145,076
Ensembl chr 3:10,041,826...10,144,388
JBrowse link
G Acaca acetyl-CoA carboxylase alpha increases phosphorylation ISO crizotinib results in increased phosphorylation of ACACA protein CTD PMID:23707608 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation
multiple interactions
ISO crizotinib results in decreased phosphorylation of AKT1 protein
EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]
CTD PMID:22553343, PMID:22729845 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Alk ALK receptor tyrosine kinase decreases response to substance
affects response to substance
decreases activity
increases mutagenesis
decreases stability
decreases phosphorylation
multiple interactions
ISO ALK gene mutant form results in decreased susceptibility to crizotinib; ALK gene SNP results in decreased susceptibility to crizotinib; ALK protein mutant form results in decreased susceptibility to crizotinib
ALK protein affects the susceptibility to crizotinib
crizotinib results in decreased activity of ALK protein mutant form
crizotinib results in increased mutagenesis of ALK gene mutant form; crizotinib results in increased mutagenesis of ALK protein mutant form
crizotinib results in decreased stability of ALK protein mutant form
crizotinib results in decreased phosphorylation of ALK protein; crizotinib results in decreased phosphorylation of ALK protein mutant form
crizotinib results in decreased activity of ALK protein; crizotinib results in decreased activity of ALK protein mutant form
[ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK gene mutant form] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK protein mutant form] which results in decreased susceptibility to crizotinib; [crizotinib results in increased mutagenesis of ALK protein mutant form] which results in increased activity of ALK protein; [Ethylnitrosourea results in increased mutagenesis of ALK protein] inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]; [Ethylnitrosourea results in increased mutagenesis of ALK protein] which results in decreased susceptibility to crizotinib; ALK gene SNP inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein mutant form]; ALK protein mutant form inhibits the reaction [crizotinib binds to and results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [crizotinib results in decreased activity of ALK protein]; ALK protein mutant form inhibits the reaction [crizotinib results in decreased phosphorylation of ALK protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein]; crizotinib results in decreased phosphorylation of and results in decreased activity of ALK protein mutant form
CTD PMID:20979473, PMID:21030459, PMID:21502504, PMID:21767331, PMID:21791641, PMID:21812414, PMID:21838707, PMID:21948233, PMID:22034911, PMID:22072639, PMID:22129595, PMID:22235099, PMID:22277784, PMID:22286764, PMID:22553343, PMID:22659414, PMID:22789543, PMID:22912387, PMID:23104988, PMID:29458018 NCBI chr 6:22,696,415...23,203,791
Ensembl chr 6:22,696,397...23,203,775
JBrowse link
G Bcl2l11 BCL2 like 11 increases expression
multiple interactions
affects response to substance
ISO crizotinib results in increased expression of BCL2L11 protein
BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased expression of BCL2L11 protein]
BCL2L11 protein affects the susceptibility to crizotinib
CTD PMID:22729845 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions
ISO crizotinib results in decreased expression of BIRC2 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC2 protein]
CTD PMID:22729845 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
ISO crizotinib results in decreased expression of BIRC5 protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of BIRC5 protein]
CTD PMID:22729845 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Cacna1c calcium voltage-gated channel subunit alpha1 C decreases activity ISO crizotinib results in decreased activity of CACNA1C protein CTD PMID:23707608 NCBI chr 4:150,635,808...151,270,790
Ensembl chr 4:150,641,066...150,829,913
JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage
increases activity
ISO BCL2L11 protein affects the reaction [crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [crizotinib results in increased cleavage of CASP3 protein]
[crizotinib co-treated with 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo(h)(1,6)naphthyridin-2(1H)-one] results in increased cleavage of CASP3 protein
crizotinib results in increased activity of CASP3 protein
CTD PMID:22729845, PMID:22789543, PMID:23707608 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 increases activity ISO crizotinib results in increased activity of CASP7 protein CTD PMID:23707608 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Casp8 caspase 8 increases cleavage ISO Crizotinib results in increased cleavage of CASP8 protein CTD PMID:31706006 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Cd44 CD44 molecule (Indian blood group) decreases expression ISO crizotinib results in decreased expression of CD44 mRNA; crizotinib results in decreased expression of CD44 protein CTD PMID:22973962 NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
JBrowse link
G Cda cytidine deaminase decreases expression
multiple interactions
ISO crizotinib results in decreased expression of CDA protein
[crizotinib results in decreased expression of CDA protein] which results in increased susceptibility to gemcitabine
CTD PMID:22973962 NCBI chr 5:156,703,579...156,734,541
Ensembl chr 5:156,703,579...156,734,541
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein CTD PMID:22683780 NCBI chr11:87,338,606...87,356,644
Ensembl chr11:87,778,312...87,815,043
JBrowse link
G Egf epidermal growth factor multiple interactions
decreases response to substance
ISO EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein]; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to crizotinib] CTD PMID:22553343 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
multiple interactions
ISO EGFR protein mutant form results in decreased susceptibility to crizotinib; EGFR protein results in decreased susceptibility to crizotinib
[EGFR protein results in increased phosphorylation of EGFR protein] which results in decreased susceptibility to crizotinib; EGFR protein promotes the reaction [EGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]
CTD PMID:21791641, PMID:22235099, PMID:22277784, PMID:22553343 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eml4 EMAP like 4 decreases stability
multiple interactions
increases mutagenesis
ISO crizotinib results in decreased stability of EML4 protein mutant form
[crizotinib results in increased mutagenesis of EML4 gene mutant form] which results in decreased susceptibility to crizotinib
CTD PMID:21502504, PMID:22912387 NCBI chr 6:6,618,370...6,674,550
Ensembl chr 6:6,619,076...6,674,554
JBrowse link
G Epcam epithelial cell adhesion molecule decreases expression ISO crizotinib results in decreased expression of EPCAM mRNA; crizotinib results in decreased expression of EPCAM protein CTD PMID:22973962 NCBI chr 6:11,282,194...11,308,870
Ensembl chr 6:11,281,964...11,298,216
JBrowse link
G F3 coagulation factor III, tissue factor increases expression ISO crizotinib results in increased expression of F3 protein CTD PMID:25569083 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Fads2 fatty acid desaturase 2 increases expression ISO crizotinib results in increased expression of FADS2 mRNA CTD PMID:23707608 NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
JBrowse link
G Fasn fatty acid synthase increases expression ISO crizotinib results in increased expression of FASN mRNA CTD PMID:23707608 NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
JBrowse link
G Fgfr1 Fibroblast growth factor receptor 1 multiple interactions ISO [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
JBrowse link
G Fshb follicle stimulating hormone subunit beta decreases secretion ISO crizotinib results in decreased secretion of FSHB protein CTD PMID:22488744 NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Crizotinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions
decreases response to substance
ISO EGFR protein promotes the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:22553343 NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] CTD PMID:22683780 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase increases expression ISO crizotinib results in increased expression of HMGCR mRNA CTD PMID:23707608 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Hmgcs1 3-hydroxy-3-methylglutaryl-CoA synthase 1 increases expression ISO crizotinib results in increased expression of HMGCS1 mRNA CTD PMID:23707608 NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
JBrowse link
G Insig1 insulin induced gene 1 increases expression ISO crizotinib results in increased expression of INSIG1 mRNA CTD PMID:23707608 NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO crizotinib results in decreased activity of KCNH2 protein CTD PMID:23707608 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Kit KIT proto-oncogene receptor tyrosine kinase decreases response to substance ISO KIT gene mutant form results in decreased susceptibility to crizotinib CTD PMID:22277784 NCBI chr14:35,072,131...35,149,638
Ensembl chr14:35,072,108...35,149,610
JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases response to substance ISO KRAS protein mutant form results in decreased susceptibility to crizotinib CTD PMID:22235099 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Lck LCK proto-oncogene, Src family tyrosine kinase decreases activity ISO crizotinib results in decreased activity of LCK protein CTD PMID:21812414 NCBI chr 5:147,750,976...147,779,627
Ensembl chr 5:147,750,973...147,761,983
JBrowse link
G Lhb luteinizing hormone subunit beta decreases secretion ISO crizotinib results in decreased secretion of LHB protein CTD PMID:22488744 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK1 protein]; crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK1 protein]; EGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein] CTD PMID:21266357, PMID:21502504, PMID:22034911, PMID:22553343, PMID:22683780, PMID:22729845, PMID:23104988 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MAPK3 protein]; Crizotinib inhibits the reaction [ALK protein mutant form results in increased phosphorylation of MAPK3 protein]; EGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; TGFA protein inhibits the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]
crizotinib results in decreased phosphorylation of MAPK3 protein
CTD PMID:21266357, PMID:21502504, PMID:22034911, PMID:22553343, PMID:22683780, PMID:22729845, PMID:23104988 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase decreases activity
affects response to substance
increases response to substance
increases mutagenesis
multiple interactions
decreases phosphorylation
ISO crizotinib results in decreased activity of MET protein
MET protein affects the susceptibility to Crizotinib
MET gene mutant form results in increased susceptibility to crizotinib
crizotinib results in increased mutagenesis of MET protein
[5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in increased mutagenesis of MET protein] which results in decreased susceptibility to Crizotinib; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of CRKL protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK1 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of MAPK3 protein; [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; [Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein; [Crizotinib results in decreased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one] inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one results in decreased phosphorylation of MET protein]; [Crizotinib results in increased mutagenesis of MET protein] inhibits the reaction [Crizotinib binds to and results in decreased activity of MET protein]; [PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Crizotinib binds to and results in decreased activity of MET protein; Crizotinib inhibits the reaction [5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one binds to and results in decreased activity of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of AKT1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK1 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MAPK3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of MET protein]; MET gene mutant form promotes the reaction [Crizotinib results in decreased phosphorylation of STAT3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased cleavage of CASP3 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BCL2L11 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC2 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of BIRC5 protein]; MET gene mutant form promotes the reaction [Crizotinib results in increased expression of XIAP protein]
CTD PMID:21266357, PMID:21405128, PMID:21812414, PMID:22233293, PMID:22683780, PMID:22729845, PMID:22948846, PMID:31639374, PMID:31706006 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Mst1r macrophage stimulating 1 receptor decreases activity ISO crizotinib results in decreased activity of MST1R protein CTD PMID:21812414 NCBI chr 8:116,686,601...116,700,132
Ensembl chr 8:116,686,601...116,700,132
JBrowse link
G Mycn MYCN proto-oncogene, bHLH transcription factor multiple interactions ISO Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN mRNA]; Crizotinib inhibits the reaction [ALK protein results in increased expression of MYCN protein] CTD PMID:22286764 NCBI chr 6:38,222,554...38,228,419
Ensembl chr 6:38,222,555...38,228,379
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
ISO Crizotinib results in increased cleavage of PARP1 protein
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Crizotinib results in increased cleavage of PARP1 protein]
CTD PMID:31639374, PMID:31706006 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Prom1 prominin 1 decreases expression ISO crizotinib results in decreased expression of PROM1 mRNA; crizotinib results in decreased expression of PROM1 protein CTD PMID:22973962 NCBI chr14:71,532,321...71,637,400
Ensembl chr14:71,533,063...71,637,417
JBrowse link
G Ros1 ROS proto-oncogene 1 , receptor tyrosine kinase decreases phosphorylation ISO crizotinib results in decreased phosphorylation of ROS protein mutant form CTD PMID:22617245 NCBI chr20:33,100,190...33,323,544
Ensembl chr20:33,100,191...33,323,367
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation ISO crizotinib results in decreased phosphorylation of RPS6 protein CTD PMID:22034911 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Scn5a sodium voltage-gated channel alpha subunit 5 decreases activity ISO crizotinib results in decreased activity of SCN5A protein CTD PMID:23707608 NCBI chr 8:128,169,191...128,266,681
Ensembl chr 8:128,169,191...128,266,639
JBrowse link
G Srebf2 sterol regulatory element binding transcription factor 2 increases expression ISO crizotinib results in increased expression of SREBF2 mRNA CTD PMID:23707608 NCBI chr 7:123,381,082...123,438,605
Ensembl chr 7:123,381,077...123,438,603
JBrowse link
G Stat3 signal transducer and activator of transcription 3 decreases phosphorylation
multiple interactions
ISO crizotinib results in decreased phosphorylation of STAT3 protein
[[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein] which results in increased phosphorylation of STAT3 protein; MET gene mutant form promotes the reaction [crizotinib results in decreased phosphorylation of STAT3 protein]
CTD PMID:22034911, PMID:22553343, PMID:22683780, PMID:22729845 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Tek TEK receptor tyrosine kinase decreases activity ISO crizotinib results in decreased activity of TEK protein CTD PMID:21812414 NCBI chr 5:113,725,717...113,852,799
Ensembl chr 5:113,725,717...113,852,799
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions
decreases response to substance
ISO EGFR protein promotes the reaction [TGFA protein results in decreased susceptibility to crizotinib]; Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of AKT1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK1 protein]; TGFA protein inhibits the reaction [crizotinib results in decreased phosphorylation of MAPK3 protein] CTD PMID:22553343 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases response to substance ISO TWIST1 protein results in decreased susceptibility to crizotinib CTD PMID:22155737 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
G Vim vimentin decreases expression ISO crizotinib results in decreased expression of VIM protein CTD PMID:22973962 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression
multiple interactions
ISO crizotinib results in decreased expression of XIAP protein
MET gene mutant form promotes the reaction [crizotinib results in increased expression of XIAP protein]
CTD PMID:22729845 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
domperidone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A affects response to substance ISO ABCB1 gene SNP affects the susceptibility to Domperidone CTD PMID:21063774 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Adra1d adrenoceptor alpha 1D affects response to substance ISO ADRA1D gene SNP affects the susceptibility to Domperidone CTD PMID:21063774 NCBI chr 3:124,129,558...124,145,566
Ensembl chr 3:124,129,558...124,145,566
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 multiple interactions ISO Domperidone inhibits the reaction [Indomethacin results in increased expression of CXCL2 mRNA] CTD PMID:21691039 NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions ISO Domperidone inhibits the reaction [Indomethacin results in increased expression of CXCL1 mRNA] CTD PMID:21691039 NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases expression ISO Domperidone results in increased expression of CYP1A1 mRNA CTD PMID:9860486 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases hydroxylation ISO CYP1A2 protein results in increased hydroxylation of Domperidone CTD PMID:15327587 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases hydroxylation ISO CYP2B6 protein results in increased hydroxylation of Domperidone CTD PMID:15327587 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases hydroxylation ISO CYP2C8 protein results in increased hydroxylation of Domperidone CTD PMID:15327587 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 increases hydroxylation ISO CYP2D6 protein results in increased hydroxylation of Domperidone CTD PMID:15327587 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Drd1 dopamine receptor D1 multiple interactions
affects binding
ISO Cyclosporine promotes the reaction [Domperidone binds to DRD1 protein] CTD PMID:12673668 NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions
affects binding
ISO
EXP
Cyclosporine promotes the reaction [Domperidone binds to DRD2 protein]
Domperidone binds to and results in decreased activity of DRD2 protein
CTD PMID:2571179, PMID:8103596, PMID:10626749, PMID:12071432, PMID:12130853, PMID:12673668 NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
JBrowse link
G Il6 interleukin 6 decreases expression ISO Domperidone results in decreased expression of IL6 protein CTD PMID:10568223 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity
multiple interactions
affects response to substance
ISO Domperidone results in decreased activity of KCNH2 protein
Domperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
KCNH2 gene SNP affects the susceptibility to Domperidone
CTD PMID:15640612, PMID:19583963, PMID:21063774, PMID:28551711 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Mpo myeloperoxidase multiple interactions ISO Domperidone inhibits the reaction [Indomethacin results in increased activity of MPO protein] CTD PMID:21691039 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO Domperidone inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA] CTD PMID:21691039 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Prl prolactin multiple interactions
increases expression
ISO
EXP
Domperidone inhibits the reaction [Deoxyepinephrine results in decreased expression of PRL protein]; Domperidone inhibits the reaction [Dopamine results in decreased expression of PRL protein]
Domperidone results in increased expression of PRL protein
CTD PMID:1304515, PMID:1874184, PMID:6736848, PMID:8532072 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Domperidone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases expression ISO Domperidone results in decreased expression of TGFB1 protein CTD PMID:10568223 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Thra thyroid hormone receptor alpha multiple interactions ISO Domperidone binds to and results in decreased activity of THRA protein CTD PMID:25752796 NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
JBrowse link
lonafarnib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form CTD PMID:16118318 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form] CTD PMID:15090542, PMID:16118318 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein] CTD PMID:15090542 NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein] CTD PMID:16118318 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC2 protein] CTD PMID:15090542 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC3 protein] CTD PMID:15090542 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC5 protein] CTD PMID:15090542 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein CTD PMID:16118318 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein CTD PMID:16118318 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions
increases cleavage
ISO [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein
lonafarnib results in increased cleavage of CASP9 protein
CTD PMID:16118318 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of CCND1 protein] CTD PMID:15090542 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of CFLAR protein] CTD PMID:15090542 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form CTD PMID:16118318 NCBI chr 1:82,097,244...82,108,238
Ensembl chr 1:82,097,247...82,108,203
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form CTD PMID:16118318 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased activity of HRAS protein] CTD PMID:15090542 NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
JBrowse link
G Il18 interleukin 18 multiple interactions ISO geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL18 protein] CTD PMID:21430599 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL1B protein] CTD PMID:21430599 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Lmna lamin A/C decreases farnesylation ISO lonafarnib results in decreased farnesylation of LMNA protein CTD PMID:16996129 NCBI chr 2:187,842,884...187,863,552
Ensembl chr 2:187,842,885...187,863,516
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of MMP9 protein] CTD PMID:15090542 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO lonafarnib inhibits the reaction [Hydrogen Peroxide results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of NFKB1 protein] CTD PMID:15090542 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein] CTD PMID:15090542 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of PTGS2 protein] CTD PMID:15090542 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO lonafarnib results in decreased phosphorylation of and results in decreased activity of RB1 protein CTD PMID:12673674 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO lonafarnib inhibits the reaction [Hydrogen Peroxide results in increased activity of RELA protein]; lonafarnib inhibits the reaction [Okadaic Acid results in increased activity of RELA protein]; lonafarnib inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of RELA protein]; lonafarnib inhibits the reaction [TNF protein affects the localization of RELA protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of RELA protein] CTD PMID:15090542 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rheb Ras homolog, mTORC1 binding decreases activity
multiple interactions
ISO lonafarnib results in decreased activity of RHEB protein
[lonafarnib results in decreased activity of RHEB protein] which results in increased susceptibility to Cisplatin
CTD PMID:20554106 NCBI chr 4:6,827,429...6,873,384
Ensembl chr 4:6,827,429...6,873,383
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO lonafarnib inhibits the reaction [TNF protein affects the localization of RELA protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of HRAS protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased activity of RELA protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BCL2A1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC3 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of BIRC5 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of CFLAR protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of TRAF1 protein]; lonafarnib inhibits the reaction [TNF protein results in increased expression of XIAP protein]; lonafarnib inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
geraniol promotes the reaction [lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]]; lonafarnib inhibits the reaction [[Alendronate co-treated with Lovastatin co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of TNF protein]
CTD PMID:15090542, PMID:21430599 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Traf1 TNF receptor-associated factor 1 multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of TRAF1 protein] CTD PMID:15090542 NCBI chr 3:14,003,340...14,022,955
Ensembl chr 3:14,003,340...14,022,672
JBrowse link
G Xiap X-linked inhibitor of apoptosis multiple interactions ISO lonafarnib inhibits the reaction [TNF protein results in increased expression of XIAP protein] CTD PMID:15090542 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
naratriptan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Htr1b 5-hydroxytryptamine receptor 1B affects binding ISO naratriptan binds to HTR1B protein CTD PMID:9170336 NCBI chr 8:89,113,984...89,130,830
Ensembl chr 8:89,129,453...89,130,991
JBrowse link
G Htr1d 5-hydroxytryptamine receptor 1D affects binding ISO naratriptan binds to HTR1D protein CTD PMID:9170336 NCBI chr 5:154,780,958...154,801,505
Ensembl chr 5:154,800,226...154,801,350
JBrowse link
paliperidone palmitate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A affects abundance
multiple interactions
increases export
increases transport
affects response to substance
decreases activity
ISO
EXP
ABCB1 gene polymorphism affects the abundance of Paliperidone Palmitate; ABCB1 protein affects the abundance of Paliperidone Palmitate
Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Paliperidone Palmitate]
ABCB1A protein results in increased transport of Paliperidone Palmitate
ABCB1A protein affects the susceptibility to Paliperidone Palmitate
Paliperidone Palmitate results in decreased activity of ABCB1 protein
Paliperidone Palmitate inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin]
ABCB1 protein results in increased transport of Paliperidone Palmitate
CTD PMID:15502009, PMID:16118767, PMID:16810505, PMID:16936711, PMID:17541883, PMID:22691713 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B affects response to substance ISO ABCB1B protein affects the susceptibility to Paliperidone Palmitate CTD PMID:15502009 NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases activity ISO Paliperidone Palmitate results in decreased activity of ABCB4 protein CTD PMID:28437613 NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO Paliperidone Palmitate inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone] CTD PMID:18834354 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Bdnf brain-derived neurotrophic factor increases expression EXP Paliperidone Palmitate results in increased expression of BDNF mRNA CTD PMID:21220416 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects abundance ISO CYP2D6 gene polymorphism affects the abundance of Paliperidone Palmitate; CYP2D6 protein affects the abundance of Paliperidone Palmitate CTD PMID:10639689, PMID:15089809, PMID:17541883 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions
affects binding
ISO
EXP
Paliperidone Palmitate binds to and results in decreased activity of DRD2 protein
Paliperidone Palmitate binds to DRD2 protein
CTD PMID:19713555, PMID:22437487 NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
JBrowse link
G Fads2 fatty acid desaturase 2 increases expression
multiple interactions
EXP Paliperidone Palmitate results in increased expression of FADS2 mRNA
[Paliperidone Palmitate results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated
CTD PMID:21458237 NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
JBrowse link
G Htr2a 5-hydroxytryptamine receptor 2A affects binding
multiple interactions
ISO
EXP
Paliperidone Palmitate binds to HTR2A protein
Paliperidone Palmitate binds to and results in decreased activity of HTR2A protein
CTD PMID:7520908, PMID:19713555, PMID:22437487 NCBI chr15:56,666,152...56,732,469
Ensembl chr15:56,666,012...56,735,382
JBrowse link
G Htr7 5-hydroxytryptamine receptor 7 multiple interactions ISO [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein CTD PMID:18996971, PMID:19509219, PMID:20827463 NCBI chr 1:254,547,964...254,671,811
Ensembl chr 1:254,547,620...254,671,778
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO Paliperidone Palmitate results in decreased activity of KCNH2 protein CTD PMID:21394035 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Prl prolactin increases expression ISO Paliperidone Palmitate results in increased expression of PRL protein CTD PMID:17460786, PMID:19825908 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
pimozide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bcl2 BCL2, apoptosis regulator decreases expression ISO Pimozide results in decreased expression of BCL2 mRNA CTD PMID:12130671 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
EXP istradefylline inhibits the reaction [Pimozide results in increased expression of FOS protein]; Tropicamide promotes the reaction [Pimozide results in increased expression of FOS protein] CTD PMID:19467297 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Kcna10 potassium voltage-gated channel subfamily A member 10 multiple interactions ISO Pimozide inhibits the reaction [KCNA10 protein results in increased transport of Potassium] CTD PMID:10836990 NCBI chr 2:209,920,590...209,932,665
Ensembl chr 2:209,920,590...209,932,665
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 multiple interactions
decreases activity
ISO Pimozide inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
Pimozide results in decreased activity of KCNH2 protein
CTD PMID:15671647, PMID:19583963, PMID:21158687, PMID:24052561 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions EXP Pimozide results in decreased secretion of and results in decreased glycosylation of LHB protein CTD PMID:3896764 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Prl prolactin increases expression ISO Pimozide results in increased expression of PRL protein CTD PMID:8915564 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
risperidone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A affects abundance
multiple interactions
increases export
increases transport
decreases activity
affects response to substance
increases response to substance
ISO
EXP
ABCB1 gene polymorphism affects the abundance of Risperidone; ABCB1 protein affects the abundance of Risperidone
Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Risperidone]
ABCB1A protein results in increased transport of Risperidone
Risperidone results in decreased activity of ABCB1 protein
ABCB1A protein affects the susceptibility to Risperidone
ABCB1 protein results in increased transport of Risperidone
Risperidone inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin]
ABCB1 protein results in increased susceptibility to Risperidone
ABCB1 gene polymorphism affects the susceptibility to Risperidone; ABCB1 protein affects the susceptibility to Risperidone
CTD PMID:15502009, PMID:16118767, PMID:16810505, PMID:16936711, PMID:17054409, PMID:17541883, PMID:18708991, PMID:19997080, PMID:20563569, PMID:21449914, PMID:22623266, PMID:22691713 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcb1b ATP-binding cassette, subfamily B (MDR/TAP), member 1B affects response to substance ISO ABCB1B protein affects the susceptibility to Risperidone CTD PMID:15502009 NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO Risperidone inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone]; Risperidone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate] CTD PMID:18834354 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions
increases expression
ISO Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] CTD PMID:20564506 NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
JBrowse link
G Bdnf brain-derived neurotrophic factor decreases expression
multiple interactions
EXP
ISO
Risperidone results in decreased expression of BDNF mRNA
BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]
Risperidone inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA]
CTD PMID:12393228, PMID:17442543, PMID:19997080 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Calm2 calmodulin 2 increases expression EXP Risperidone results in increased expression of CALM2 mRNA CTD PMID:19289156 NCBI chr 6:11,067,675...11,080,078
Ensembl chr15:65,506,874...65,507,968
JBrowse link
G Camk2a calcium/calmodulin-dependent protein kinase II alpha decreases expression EXP Risperidone results in decreased expression of CAMK2A protein CTD PMID:19289156 NCBI chr18:56,193,978...56,295,869
Ensembl chr18:56,193,978...56,295,869
JBrowse link
G Camk4 calcium/calmodulin-dependent protein kinase IV decreases expression EXP Risperidone results in decreased expression of CAMK4 protein CTD PMID:19289156 NCBI chr18:25,746,878...25,975,962
Ensembl chr18:25,749,098...25,965,957
JBrowse link
G Camkk1 calcium/calmodulin-dependent protein kinase kinase 1 decreases expression EXP Risperidone results in decreased expression of CAMKK1 protein CTD PMID:19289156 NCBI chr10:59,585,023...59,608,180
Ensembl chr10:59,585,072...59,608,165
JBrowse link
G Camkk2 calcium/calmodulin-dependent protein kinase kinase 2 decreases expression EXP Risperidone results in decreased expression of CAMKK2 protein CTD PMID:19289156 NCBI chr12:39,253,409...39,302,601
Ensembl chr12:39,253,409...39,302,601
JBrowse link
G Casp3 caspase 3 multiple interactions
increases activity
ISO Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP3 protein] CTD PMID:22700542 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp7 caspase 7 multiple interactions
increases activity
ISO Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP7 protein] CTD PMID:22700542 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions
increases expression
ISO Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein]
Risperidone results in increased expression of CEBPA mRNA; Risperidone results in increased expression of CEBPA protein
CTD PMID:20564506 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Chrm4 cholinergic receptor, muscarinic 4 affects response to substance ISO CHRM4 affects the susceptibility to Risperidone CTD PMID:21269601 NCBI chr 3:80,833,272...80,841,165
Ensembl chr 3:80,833,272...80,841,006
JBrowse link
G Comt catechol-O-methyltransferase increases expression EXP Risperidone results in increased expression of COMT mRNA CTD PMID:15964593 NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
JBrowse link
G Crh corticotropin releasing hormone decreases expression ISO Risperidone results in decreased expression of CRH mRNA CTD PMID:16205782 NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
increases expression
EXP DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein] CTD PMID:16144542 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing
increases metabolic processing
increases response to substance
affects response to substance
decreases hydroxylation
decreases metabolic processing
affects abundance
multiple interactions
ISO CYP2D6 gene polymorphism affects the metabolism of Risperidone; CYP2D6 protein affects the metabolism of Risperidone
CYP2D6 protein results in increased metabolism of Risperidone
CYP2D6 protein results in increased susceptibility to Risperidone
CYP2D6 gene polymorphism affects the susceptibility to Risperidone; CYP2D6 protein polymorphism affects the susceptibility to Risperidone
CYP2D6 gene polymorphism results in decreased hydroxylation of Risperidone
CYP2D6 gene polymorphism results in decreased metabolism of Risperidone
CYP2D6 gene polymorphism affects the abundance of Risperidone; CYP2D6 protein affects the abundance of Risperidone
CYP2D6 gene polymorphism affects the metabolism of and affects the abundance of Risperidone; CYP2D6 protein affects the metabolism of and affects the abundance of Risperidone
CTD PMID:10639689, PMID:15089809, PMID:15260906, PMID:15565299, PMID:15669884, PMID:16044105, PMID:17224713, PMID:17541883, PMID:18708991, PMID:19387994, PMID:20332423, PMID:20563569, PMID:21449914, PMID:22623266, PMID:22745940, PMID:23609392 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 affects abundance
increases metabolic processing
ISO CYP3A5 gene polymorphism affects the abundance of Risperidone; CYP3A5 protein affects the abundance of Risperidone
CYP3A5 protein results in increased metabolism of Risperidone
CTD PMID:18708991, PMID:20332423 NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
JBrowse link
G Drd2 dopamine receptor D2 multiple interactions
affects binding
increases response to substance
affects response to substance
ISO
EXP
Risperidone binds to and results in decreased activity of DRD2 protein
Risperidone binds to DRD2 protein
[Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein]; Risperidone binds to and results in decreased activity of DRD2 protein; Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein]
DRD2 gene polymorphism results in increased susceptibility to Risperidone; DRD2 gene SNP results in increased susceptibility to Risperidone; DRD2 protein results in increased susceptibility to Risperidone
DRD2 gene polymorphism affects the susceptibility to Risperidone
CTD PMID:1380082, PMID:7520908, PMID:8804920, PMID:10831489, PMID:12191584, PMID:15710053, PMID:15716360, PMID:16033416, PMID:16144542, PMID:16513859, PMID:18058087, PMID:19339912, PMID:19640686, PMID:19910723, PMID:20361897, PMID:20375926, PMID:21869689, PMID:22437487, PMID:22967779 NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
JBrowse link
G Drd3 dopamine receptor D3 increases response to substance ISO DRD3 gene SNP results in increased susceptibility to Risperidone; DRD3 protein results in increased susceptibility to Risperidone CTD PMID:19506579, PMID:19997080 NCBI chr11:61,819,102...61,883,223
Ensembl chr11:61,822,077...61,874,327
JBrowse link
G Dvl3 dishevelled segment polarity protein 3 multiple interactions
increases expression
EXP DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein] CTD PMID:16144542 NCBI chr11:84,051,177...84,068,479
Ensembl chr11:84,051,078...84,068,302
JBrowse link
G Egr1 early growth response 1 decreases expression EXP Risperidone results in decreased expression of EGR1 protein CTD PMID:17028028 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Egr2 early growth response 2 decreases expression EXP Risperidone results in decreased expression of EGR2 protein CTD PMID:17028028 NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 increases phosphorylation EXP Risperidone results in increased phosphorylation of ERBB2 protein CTD PMID:26961615 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
JBrowse link
G Erbb4 erb-b2 receptor tyrosine kinase 4 multiple interactions EXP Risperidone results in increased expression of and results in increased phosphorylation of ERBB4 protein CTD PMID:26961615 NCBI chr 9:75,021,790...76,178,936
Ensembl chr 9:75,021,790...75,528,644
JBrowse link
G Fads2 fatty acid desaturase 2 increases expression
multiple interactions
EXP Risperidone results in increased expression of FADS2 mRNA
[Risperidone results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated
CTD PMID:21458237 NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
JBrowse link
G Fas Fas cell surface death receptor multiple interactions
increases expression
ISO Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] CTD PMID:20564506 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
EXP Risperidone promotes the reaction [Rotenone results in increased expression of FOS mRNA]
Risperidone results in increased expression of FOS mRNA
CTD PMID:11516571, PMID:17442543 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Fshb follicle stimulating hormone subunit beta affects expression ISO Risperidone affects the expression of FSHB protein CTD PMID:18838228 NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha increases expression
multiple interactions
EXP Risperidone results in increased expression of GSK3A protein
DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein]
CTD PMID:16144542 NCBI chr 1:82,097,244...82,108,238
Ensembl chr 1:82,097,247...82,108,203
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
increases expression
EXP DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein] CTD PMID:16144542 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Hmgcr 3-hydroxy-3-methylglutaryl-CoA reductase increases expression ISO Risperidone results in increased expression of HMGCR mRNA CTD PMID:17052361 NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
JBrowse link
G Homer1 homer scaffold protein 1 increases expression EXP Risperidone results in increased expression of HOMER1 mRNA CTD PMID:20147574 NCBI chr 2:22,909,550...23,012,303
Ensembl chr 2:22,909,569...23,009,678
JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A increases response to substance
multiple interactions
EXP HTR1A protein results in increased susceptibility to Risperidone
N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [HTR1A protein results in increased susceptibility to Risperidone]
CTD PMID:17530476 NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
JBrowse link
G Htr2a 5-hydroxytryptamine receptor 2A increases response to substance
affects binding
multiple interactions
affects response to substance
ISO
EXP
HTR2A gene SNP results in increased susceptibility to Risperidone; HTR2A protein results in increased susceptibility to Risperidone
Risperidone binds to HTR2A protein
Risperidone binds to and results in decreased activity of HTR2A protein; Risperidone inhibits the reaction [Ketanserin binds to HTR2A protein]
HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; Risperidone binds to and results in decreased activity of HTR2A protein
HTR2A protein affects the susceptibility to Risperidone
CTD PMID:7520908, PMID:11927170, PMID:12191584, PMID:16314884, PMID:16948927, PMID:19997080, PMID:22437487 NCBI chr15:56,666,152...56,732,469
Ensembl chr15:56,666,012...56,735,382
JBrowse link
G Htr2c 5-hydroxytryptamine receptor 2C affects response to substance
multiple interactions
increases response to substance
ISO HTR2C gene polymorphism affects the susceptibility to Risperidone; HTR2C protein affects the susceptibility to Risperidone
HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]
HTR2C protein results in increased susceptibility to Risperidone
CTD PMID:19142101, PMID:19997080 NCBI chr  X:118,084,520...118,318,040
Ensembl chr  X:118,084,890...118,318,039
JBrowse link
G Htr6 5-hydroxytryptamine receptor 6 multiple interactions ISO HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein] CTD PMID:19997080 NCBI chr 5:157,501,202...157,518,870
Ensembl chr 5:157,503,040...157,518,631
JBrowse link
G Htr7 5-hydroxytryptamine receptor 7 multiple interactions ISO 2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Clozapine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Cyproheptadine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Mianserin inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Risperidone binds to and results in decreased activity of HTR7 protein; SB 269970 inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein] CTD PMID:18996971, PMID:19509219, PMID:20827463 NCBI chr 1:254,547,964...254,671,811
Ensembl chr 1:254,547,620...254,671,778
JBrowse link
G Inha inhibin subunit alpha multiple interactions ISO Risperidone results in increased expression of [INHA protein binds to INHBB protein] CTD PMID:18838228 NCBI chr 9:82,700,482...82,703,383
Ensembl chr 9:82,700,468...82,703,400
JBrowse link
G Inhbb inhibin subunit beta B multiple interactions ISO Risperidone results in increased expression of [INHA protein binds to INHBB protein] CTD PMID:18838228 NCBI chr13:35,436,532...35,442,222
Ensembl chr13:35,436,532...35,442,222
JBrowse link
G Ins2 insulin 2 increases expression ISO Risperidone results in increased expression of INS protein CTD PMID:11927762, PMID:16601995 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 multiple interactions ISO Risperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium] CTD PMID:21158687 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions
increases expression
ISO Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] CTD PMID:20564506 NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
JBrowse link
G Maoa monoamine oxidase A affects response to substance
increases response to substance
ISO MAOA gene polymorphism affects the susceptibility to Risperidone
MAOA protein results in increased susceptibility to Risperidone
CTD PMID:22544010 NCBI chr  X:6,554,698...6,620,722
Ensembl chr  X:6,554,698...6,620,722
JBrowse link
G Maob monoamine oxidase B increases expression EXP Risperidone results in increased expression of MAOB mRNA CTD PMID:15964593 NCBI chr  X:6,430,694...6,533,520
Ensembl chr  X:6,430,594...6,533,534
JBrowse link
G Map2 microtubule-associated protein 2 increases expression EXP Risperidone results in increased expression of MAP2 mRNA CTD PMID:15079866 NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
JBrowse link
G Ngfr nerve growth factor receptor decreases expression EXP Risperidone results in decreased expression of NGFR mRNA CTD PMID:12111809, PMID:16513140 NCBI chr10:83,389,828...83,408,061
Ensembl chr10:83,389,847...83,408,061
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA] CTD PMID:21402137 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nrg1 neuregulin 1 increases expression EXP Risperidone results in increased expression of NRG1 protein CTD PMID:26961615 NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression
multiple interactions
ISO Risperidone results in increased expression of PPARG mRNA; Risperidone results in increased expression of PPARG protein
Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein]
CTD PMID:20564506 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppp3ca protein phosphatase 3 catalytic subunit alpha multiple interactions
decreases expression
EXP [Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein
Risperidone results in decreased expression of PPP3CA mRNA; Risperidone results in decreased expression of PPP3CA protein
CTD PMID:16033416 NCBI chr 2:241,909,332...242,186,861
Ensembl chr 2:241,909,832...242,184,854
JBrowse link
G Prl prolactin multiple interactions
increases secretion
increases expression
ISO
EXP
[Risperidone co-treated with Clozapine] results in increased expression of PRL protein; Aripiprazole inhibits the reaction [Risperidone results in increased secretion of PRL protein]; BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]
Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein]
CTD PMID:1380082, PMID:9696519, PMID:9989566, PMID:10084644, PMID:11048906, PMID:11155212, PMID:11561931, PMID:11927762, PMID:12902212, PMID:12974991, PMID:15206663, PMID:15286066, PMID:15289996, PMID:15669890, PMID:15960571, PMID:16379509, PMID:16730335, PMID:17224713, PMID:18063941, PMID:18080171, PMID:18466271, PMID:18562423, PMID:18759643, PMID:18838228, PMID:19653986, PMID:19825908, PMID:19906340, PMID:19997080, PMID:20373475, PMID:20661022, PMID:20814333 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
G Rgs2 regulator of G-protein signaling 2 increases expression EXP Risperidone results in increased expression of RGS2 mRNA CTD PMID:11516571 NCBI chr13:60,846,458...60,849,061
Ensembl chr13:60,846,308...60,849,094
JBrowse link
G S100b S100 calcium binding protein B increases secretion EXP Risperidone results in increased secretion of S100B protein CTD PMID:18421423 NCBI chr20:13,130,633...13,142,856
Ensembl chr20:13,130,636...13,142,856
JBrowse link
G Slc17a6 solute carrier family 17 member 6 increases expression ISO Risperidone results in increased expression of SLC17A6 mRNA; Risperidone results in increased expression of SLC17A6 protein CTD PMID:18155072 NCBI chr 1:106,980,463...107,038,717
Ensembl chr 1:106,998,623...107,038,704
JBrowse link
G Snap25 synaptosome associated protein 25 affects response to substance ISO SNAP25 gene SNP affects the susceptibility to Risperidone CTD PMID:15823421 NCBI chr 3:129,697,408...129,788,417
Ensembl chr 3:129,599,353...129,788,400
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions
increases expression
EXP Risperidone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]; Risperidone inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]
Risperidone results in increased expression of SOD1 mRNA
CTD PMID:12111809, PMID:12752374, PMID:16564057 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions
increases expression
ISO Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein]
Risperidone results in increased expression of SREBF1 mRNA; Risperidone results in increased expression of SREBF1 protein
CTD PMID:20564506 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions EXP Risperidone inhibits the reaction [Rotenone results in decreased expression of STAT3 mRNA] CTD PMID:17442543 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Th tyrosine hydroxylase increases expression EXP Risperidone results in increased expression of TH protein CTD PMID:17028028 NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
JBrowse link
sertindole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity
multiple interactions
ISO sertindole results in decreased activity of KCNH2 protein
sertindole inhibits the reaction [KCNH2 protein results in increased transport of Thallium]
CTD PMID:16278312, PMID:21158687, PMID:24052561 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    chemical entity 19816
      atom 19814
        nonmetal atom 19690
          nitrogen atom 18565
            nitrogen molecular entity 18565
              organonitrogen compound 18338
                organonitrogen heterocyclic compound 17485
                  piperidines 7446
                    heteroarylpiperidine 143
                      (11S)-8-chloro-11-[1-(methylsulfonyl)piperidin-4-yl]-6-piperazin-1-yl-11H-benzo[5,6]cyclohepta[1,2-b]pyridine 0
                      (3R,4R)-1-\{6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl\}-4-(2,4,5-trifluorophenyl)piperidin-3-amine 0
                      (5R)-6-hydroxy-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-phenyluracil 0
                      (8aS)-7-[(6-chloronaphthalen-2-yl)sulfonyl]-8a-(methoxymethyl)-1'-pyridin-4-yltetrahydro-5H-spiro[1,3-oxazolo[3,2-a]pyrazine-2,4'-piperidin]-5-one 0
                      1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-7-piperidin-4-yl-3,4-dihydroquinolin-2(1H)-one 0
                      2-[4-(\{2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-2-oxoethyl\}amino)-4-methylpiperidin-1-yl]isonicotinic acid 0
                      3-\{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl\}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate + 12
                      3-\{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl\}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one + 0
                      4-\{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl\}piperidine-1-carboxamide + 28
                      N-(4-\{4-amino-1-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl\}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide 0
                      domperidone + 19
                      nadifloxacin + 0
                      naratriptan + 2
                      pimozide 6
                      piperidinylimidazole + 0
                      pyrazolylpiperidine + 53
                      pyridazinylpiperidine + 0
                      pyridylpiperidine + 0
                      risperidone 61
                      sertindole 1
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    subatomic particle 19814
      composite particle 19814
        hadron 19814
          baryon 19814
            nucleon 19814
              atomic nucleus 19814
                atom 19814
                  main group element atom 19702
                    p-block element atom 19702
                      carbon group element atom 19608
                        carbon atom 19597
                          organic molecular entity 19597
                            organic molecule 19522
                              organic cyclic compound 19320
                                organic heterocyclic compound 18432
                                  organic heteromonocyclic compound 16469
                                    piperidines 7446
                                      heteroarylpiperidine 143
                                        (11S)-8-chloro-11-[1-(methylsulfonyl)piperidin-4-yl]-6-piperazin-1-yl-11H-benzo[5,6]cyclohepta[1,2-b]pyridine 0
                                        (3R,4R)-1-\{6-[3-(methylsulfonyl)phenyl]pyrimidin-4-yl\}-4-(2,4,5-trifluorophenyl)piperidin-3-amine 0
                                        (5R)-6-hydroxy-5-[4-(2-hydroxyethyl)piperidin-1-yl]-5-phenyluracil 0
                                        (8aS)-7-[(6-chloronaphthalen-2-yl)sulfonyl]-8a-(methoxymethyl)-1'-pyridin-4-yltetrahydro-5H-spiro[1,3-oxazolo[3,2-a]pyrazine-2,4'-piperidin]-5-one 0
                                        1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-7-piperidin-4-yl-3,4-dihydroquinolin-2(1H)-one 0
                                        2-[4-(\{2-[(2S,5R)-2-(aminomethyl)-5-ethynylpyrrolidin-1-yl]-2-oxoethyl\}amino)-4-methylpiperidin-1-yl]isonicotinic acid 0
                                        3-\{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl\}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate + 12
                                        3-\{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl\}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one + 0
                                        4-\{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl\}piperidine-1-carboxamide + 28
                                        N-(4-\{4-amino-1-[1-(tetrahydro-2H-pyran-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl\}-2-methoxyphenyl)-1-methyl-1H-indole-2-carboxamide 0
                                        domperidone + 19
                                        nadifloxacin + 0
                                        naratriptan + 2
                                        pimozide 6
                                        piperidinylimidazole + 0
                                        pyrazolylpiperidine + 53
                                        pyridazinylpiperidine + 0
                                        pyridylpiperidine + 0
                                        risperidone 61
                                        sertindole 1
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.